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Abstract
Background: Bacterial colonization of the upper airways is a prerequisite for subsequent invasive disease. With the
introduction of the 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13), changes in pneumococcal
upper airway colonization have been described. It is, however, less evident whether the vaccines lead to compositional
changes of the upper airway microbiota. Here, we performed a case–control study using samples from a longitudinal
infant cohort from Switzerland. We compared pneumococcal carriage and the nasal microbiota within the first year of life
of healthy infants vaccinated with either PCV7 (n = 20, born in 2010) or PCV13 (n = 21, born between 2011 and 2013).
Nasal swabs were collected every second week (n = 763 in total). Pneumococcal carriage was analyzed by quantitative
PCR of the pneumococcal-specific lytA gene. Analysis of the bacterial core microbiota was performed based on 16S rRNA
sequencing and subsequent oligotyping. We exclusively performed oligotyping of the core microbiota members, which
were defined as the five most abundant bacterial families (Moraxellaceae, Streptococcaceae, Staphylococcaceae,
Corynebacteriaceae, and Pasteurellaceae). Linear mixed effect (LME) and negative binomial regression models
were used for statistical analyses.
Results: We found a higher number of samples positive for pneumococcal carriage in PCV7- compared to
PCV13-vaccinated infants (LME model; P = 0.01). In contrast, infants vaccinated in the PCV13 era had an increased alpha
diversity as measured by the richness and the Shannon Diversity Index (LME model; P = 0.003 and P = 0.01, respectively).
Accordingly, the PCV13 era was associated with clusters of a higher diversity than PCV7-associated clusters. Furthermore,
infants vaccinated with PCV13 had a higher binary-based within-subject microbiota similarity, as well as a decreased
Jensen–Shannon distance over time as compared to PCV7-vaccinated infants, indicating a higher microbiota stability in
the PCV13 era (LME model and t test; P = 0.06 and P = 0.03, respectively).
Conclusions: We hypothesize that the higher diversity and stability of the upper airway microbiota in the PCV13 era is
the result of the lower pneumococcal carriage rate. This seems to indicate that the nasal bacterial microbiota of infants
has changed in recent years as compared to the beginning of this study.
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Background
Streptococcus pneumoniae is a frequent asymptomatic
colonizer of the infant’s nasopharynx [1]. However,
pneumococcal carriage is a prerequisite for subsequent
invasive disease, such as bacteremia, pneumonia, and
meningitis [2, 3]. Due to this duality of commensalism
and pathogenicity, S. pneumoniae is alternatively defined
as a pathobiont [4].
The introduction of the pneumococcal conjugate vac-
cines (PCVs) has lowered the burden of invasive pneumo-
coccal disease (IPD), non-bacteremic pneumococcal
pneumonia, and pneumococcal otitis media in different
countries worldwide [5]. Interestingly, PCVs have pre-
vented a disproportionally high amount of otitis media
disease episodes as compared with non-bacteremic pneu-
monia or IPD cases [6]. PCVs have mainly been used for
infants; however, pneumococcal infections declined also in
adults and elderly people, mostly through the effect of
herd immunity [2, 7, 8]. It is therefore challenging to dis-
entangle the effects of herd immunity from the direct ef-
fects of the vaccines. PCVs act by targeting the capsular
polysaccharides of the most frequently isolated serotypes
of S. pneumoniae in IPD [9]. The 7-valent PCV (PCV7),
which covers seven different pneumococcal serotypes
(serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F), was recently
replaced by the 13-valent PCV (PCV13) covering 13
different pneumococcal serotypes (PCV7 serotypes plus
serotypes 1, 3, 5, 6A, 7F, and 19A). In Switzerland, PCV7
was introduced in late 2006 and subsequently replaced by
PCV13 in 2011 [10]. Regarding pneumococcal carriage,
it is not yet clear whether the PCVs led to a reduced
carriage rate. Results from various countries are dis-
cordant; while some studies found a reduction in the
overall pneumococcal carriage, others did not observe
this effect [11, 12].
Among lowering the frequency of disease, cross-
sectional studies demonstrated that PCV7 induced a
change in the prevalence of species in the upper airway
microbiota in infants and young children [13–15]. The
relative abundance of the potential pathogens Staphylo-
coccus aureus and Haemophilus influenzae, for example,
was found increased in PCV7-vaccinated infants as com-
pared to controls [15]. The upper airway microbiota of
infants is although highly personalized, dynamic, and
sensitive to perturbations [14, 16, 17]. It can thus be de-
scribed as a delicate ecosystem and vaccination as a pos-
sible disruption of its homeostasis [18, 19]. However, the
effect of PCVs, especially of PCV13, on other bacterial
species that inhabit the same niche as S. pneumoniae,
has not been extensively studied, and in particular, data
of longitudinal analyses are still scarce [20]. The higher
serotype coverage of PCV13 might, for example, have
additional effects on the microbiota composition as
compared to PCV7. This is, important, as the changes of
the upper airway microbiota caused by the PCVs could
potentially affect the susceptibility towards infectious
diseases.
As for the methodology, sequencing of distinct
variable regions of the 16S rRNA with subsequent
definitions of operational taxonomic units (OTUs)
based on 97% sequence identity has become a stand-
ard for the characterization of the microbiota [14,
17, 21]. As an alternative, oligotyping has been de-
scribed which is able to detect very subtle variations
among 16S rRNA sequences [22, 23]. However, no
variable region of the 16S rRNA is appropriate for
the pneumococcal species identification [24] and,
therefore, lytA real-time PCR has been recom-
mended for this purpose [25].
Within this study, we investigated the impact of
vaccination with PCV7 or PCV13 on the pneumo-
coccal carriage and the nasal microbiota in a
case–control study using samples from a longitudinal
cohort study of healthy infants in Switzerland. Our
aims were (1) to assess pneumococcal carriage via
quantitative PCR of the lytA gene, (2) to investigate
changes in the nasal bacterial core microbiota
composition using oligotyping, and (3) to compare
the dissimilarity and stability of the bacterial core
microbiota between the PCV7 and the PCV13
vaccine era.
Methods
Study design and nasal swab procedures
A total of 41 healthy infants, who received two doses of
either PCV7 or PCV13 within the first year of life, were
enrolled from the Basel Bern Infant Lung Development
(BILD) cohort study [26]. Twenty infants were vacci-
nated with PCV7 and 21 with PCV13. No matching be-
tween the two groups was performed. These 41 infants
were part of a previous study, where the nasal micro-
biota composition of 48 healthy infants was longitudin-
ally investigated within the first year of life [16]. In the
study here, seven infants were excluded because they ob-
tained no or only a single dose of PCV. Pregnant
mothers were recruited from the four major maternity
hospitals, and practices of obstetricians in the agglomer-
ation of Bern, Switzerland, and infants were followed
weekly within the first year of life. As described in our
previous study, information about pre-, peri-, and post-
natal history was collected in hospital records and in a
questionnaire [16]. In weekly phone interviews, study
nurses assessed the infant’s health status, respiratory
symptoms, and antibiotic prescriptions. Every second
week, a nasal swab (nasal swabs and UTM tubes from
Verridial E. Muller, Blonay, Switzerland) was collected
by the parents of the study infants and sent in a trans-
port medium within <10 days to the study center and
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frozen at −80 °C until further processing. The study par-
ents were instructed by study nurses about correct and
standardized sampling of the swabs. Like in our previous
study, nasal swabs collected during antibiotic therapy
were excluded from the study [16]. The study was ap-
proved by the ethics committee of the Canton of Bern,
Switzerland.
Quantitative real-time PCR of the pneumococcal lytA gene
DNA was extracted directly out of the swab (QIAamp
DNA Minikit, Qiagen, Hilden, Germany) using 200 μl
of transport medium. Quantitative real-time PCR
(qPCR) of the pneumococcal-specific lytA gene (en-
coding for the LytA autolysin virulence factor [27])
was performed as described by Carvalho et al. [25].
We used the lytA-CDC primers and probe. The probe
was labeled at the 5′-end with 6-carboxyfluorescin
and the Black Hole Quencher 1 (BHQ1) was placed
at the 3′-end of the probe. The assay was performed
as a 20 μl reaction using the TaqMan Universal Mas-
ter Mix (Applied Biosystems, Foster City, CA) according
to the instructions of the manufacturer. The final concen-
tration for the primers and the probe was 200 nM, and
2 μl of sample DNA was used. The experiment was car-
ried out on the QuantStudio 7 Flex Real-Time PCR Sys-
tem using 0.1 ml MicroAmp Fast 96-Well Reaction Plates
(Applied Biosystems). In each run, a standard curve was
included, using serial tenfold dilutions (equivalent to
10,000,000—10 copies of genomic DNA of the strain S.
pneumoniae 110.58, which was previously used in our
lab [28–30]; accession number CP007593). A negative
control was included in every run. The following cyc-
ling conditions were used: 50 °C for 2 min and 95 °C
for 10 min, followed by 40 cycles of 95 °C for 15 s
and 60 °C for 1 min. The results were collected using
the QuantStudio 6 and 7 Flex Software. Each sample
was measured in triplicate. We analyzed both, the
lytA quantity (number of copies) and the number of
samples positive for pneumococcal carriage (samples
with >10 lytA copies). The lytA quantity was logarith-
mically transformed for analysis.
16S rRNA sequencing
Following DNA extraction (see above), PCR of the V3–
V5 region of the 16S rRNA gene was performed using
the primer pair 341F/907R. Primer sequences were as
follows: 341F 5′-CGTATCGCCTCCCTCGCGCCATCA
GXXXXXXXXXXACTCCTACGGGAGGCAGCAG-3′,
and 907R 5′-CTATGCGCCTTGCCAGCCCGCTCAGXX
XXXXXXXXCCGTCAATTCMTTTGAGTTT-3′ where
the adaptor sequences are italicized, the template-specific
sequences are in bold, and the XXXXXXXXXX sequences
describe the sample-specific multiplex-identifier barcode.
Primers were used in a final concentration of 100 μM.
PCR was performed as a reaction mix, which included
among the primers and the extracted DNA, FastStart Taq
DNA Polymerase (1 U final), PCR Reaction Buffer without
MgCl2 (10 μM final), MgCl2 (8 μM final), and dNTPs
(0.2 mM final) (all from Roche Diagnostics, Mannheim,
Germany). The PCR conditions were set to an initial de-
naturation and enzyme activation step of 95 °C for 6 min,
followed by 35 cycles of 95 °C for 0.5 min, 59 °C for
0.5 min, 72 °C for 1.5 min, and a final elongation of 72 °C
for 10 min. PCR products were cleaned up (Wizard SV
Gel and PCR Clean-Up System, Promega, Madison, WI)
and eluted in 40 μl of double-distilled H2O. Concentration
of the PCR products was measured by the Agilent 2100
Bioanalyzer (Agilent Technologies, Basel, Switzerland).
Sequencing was performed on the 454 GS FLX Titanium
platform (Roche, Basel, Switzerland). Sequence reads were
analyzed using the PyroTagger pipeline, which comprised
quality filtering, removing of chimeras, and taxonomic as-
signment [31]. Pipeline settings were described in detail
before [14]. In brief, singleton reads were first excluded
and the read length was set to 230 nucleotides because a
loss of quality scores was observed for subsequent nucleo-
tides (data not shown). The built-in quality filtering steps
of PyroTagger included for example the exclusion of reads
in which 3% of bases had a Phred value <27, or the as-
sumption that high-abundance reads are more accurate
and therefore have a higher priority to be selected as the
representative sequence. Representative sequences were
then classified using the Phylodb, which contains 105,060
reference sequences from the SILVA (www.arb-silva.de)
and greengenes (http://greengenes.lbl.gov) databases.
Additional quality controls were as follows: Samples with
a PCR product <1.0 ng/μl, corresponding to <1 pg/μl bac-
terial DNA [16], which was recommended as the thresh-
old when working with low-density samples [32],
were excluded, as well as samples with <70 sequence
reads, and samples with >5.0% relative abundance in
common with OTUs from two negative control sam-
ples. The reads were submitted to the National Cen-
ter for Biotechnology Information Sequence Read
Archive (accession number SRP041616).
Oligotyping
We performed oligotyping of the core microbiota members,
which were defined as the five most abundant bacterial fam-
ilies (Moraxellaceae, Streptococcaceae, Staphylococcaceae,
Corynebacteriaceae, and Pasteurellaceae) [16]. Oligotyping
allows elucidating the diversity within bacterial families
based on the information that stems from the entropy
analysis of variable sites in the sequence reads [23]. Se-
quence reads of every core microbiota family were se-
lected and aligned using mothur version 1.36.1 [33].
Note that every core microbiota family was separately
aligned (using the align.seqs command and the SILVA
Mika et al. Microbiome  (2017) 5:85 Page 3 of 14
database) and sequence reads trimmed to the same
length within the microbiota family. Read length
depended therefore on the alignment of the microbiota
family in the alignment space and differed between the
families. The aligned sequence reads for each family were
then subjected to the otu2ot pipeline [34], which was im-
plemented in the R language [35], based on previous work
by Eren et al. [23]. The cutoff was set to an entropy mini-
mum of 0.6 and a minimal number of 21 sequence reads
for each oligotype (OT). The “broken-stick model” was
used to differentiate between real OTs and OTs that were
probably due to chance alone [34]. The representative
sequence of each OT, which was defined as the most
abundant unique sequence belonging to an OT [22],
was taxonomically assigned using BLAST (Basic Local
Alignment Search Tool, http://blast.ncbi.nlm.nih.gov/Blas-
t.cgi). The assignment/s with the highest “Max Score”
was/were selected. The relative abundance of each OT
was calculated as the fraction of reads of the total number
of sequence reads in the corresponding sample.
Microbiota analyses
Species richness, the Shannon Diversity Index (SDI), and
the beta diversity as measured by the Jaccard dissimilar-
ity index with non-metric multidimensional scaling
(NMDS) as ordination method, were calculated in R
using the vegan package as described before [16, 36].
Note that even though the Jaccard index is by definition
binary based, vegan calculates both the binary-, and the
abundance-based distances under the same name. We
therefore performed both the binary- and the
abundance-based dissimilarities using the same index.
The richness was calculated using the specnumber, the
SDI the diversity, and the beta diversity the vegdist and
the metaMDS function. We used the relative abundance
and the prevalence of the different OTs instead of the
commonly used operational taxonomic units (OTUs)
table as input matrix for the microbiota analyses. Clus-
tering was performed based on the OT matrix using the
Jensen–Shannon distance measure (as described by Aru-
mugam et al. [37]) and the function hclust (ward.D dis-
tance) from the stats package in R. The optimal number
of clusters was calculated via partitioning around
medoids using the pamk function from the fpc package
in R. Cluster correlation with either the PCV7 or the
PCV13 era was evaluated with the function rcorr from
the Hmisc package in R. Benjamini-Hochberg (BH) cor-
rection for multiple testing was additionally applied. The
within-subject Jaccard dissimilarity by age was performed
based on the OT table as input matrix and includes all pair-
wise comparisons from an infant within a 2-week interval
in the corresponding month of age within the first year of
life. We calculated both the abundance- and the binary-
based Jaccard dissimilarity by age. In order to investigate
the switch of an infant between clusters as a measure of
community stability, the Jensen–Shannon distance was cal-
culated using the cluster analysis as input as described by
Gajer et al. [38]. The mean of all distance values per infant
was calculated and logarithmically transformed. The lower
the distance, the less the infant changed between commu-
nity clusters.
Statistical analyses
Risk and confounding factors, such as the pre-, peri-,
and postnatal history, as well as respiratory symptoms,
were compared between PCV7- and PCV13-vaccinated
infants using chi-square tests and unpaired t tests. A
negative binomial regression (NBR) model and two dif-
ferent linear mixed effect (LME) models were performed
in R using the glmmADMB and the lme4 package with
the glmmadmb and the lmer function, respectively. We
investigated the association between the vaccine era and
the different outcome variables: pneumococcal lytA
quantity and number of samples positive, SDI, richness,
relative abundance and prevalence of OTs, and within-
subject Jaccard dissimilarity. Based on the risk and con-
founding factors, we adjusted for season and age, which
both were shown to impact the microbiota [16], as well
as for the season of birth and symptoms of lower re-
spiratory tract infection (LRTI) [26]. To investigate our
first and second aim—the analysis of the pneumococcal
carriage and the nasal core microbiota—models 1 and 2
were performed: Model 1 was used for the following
outcome variables: lytA quantity and number of samples
positive, OT prevalence based on the binary matrix, SDI,
and richness. The lytA quantity corresponds to the total
number of lytA copies, while the number of samples
positive represents the number of samples with >10 lytA
copies. The fixed effects for model 1 were age, season,
season of birth, symptoms of LRTI, and vaccine era. Be-
cause the outcome variable relative abundance of OTs
was not normally distributed, we used a negative bino-
mial regression (NBR) model as suggested before [39].
Model 2 was therefore used for the relative abundance
of the OTs as outcome variable. Same as for model 1 the
fixed effects were age, season, season of birth, symptoms
of LRTI, and vaccine era. To investigate our third
aim—the dissimilarity and stability of the core microbio-
ta—model 3 was performed for the Jaccard dissimilarity
by age as outcome variable. We therefore stratified the
dissimilarity to the corresponding month of age. Because
the Jaccard dissimilarity is based on pairwise compari-
sons between two samples at two different time points,
the variable does not allow to unambiguously defining
the season for each value. We therefore decided to omit
this fixed effect. The fixed effects were: age, season of
birth, and vaccine era. As random effects we entered for
all three models intercepts for the infants, as well as by-
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infant random slopes for the effect of the vaccine era.
The difference of the mean Jensen–Shannon distance
between the PCV7 and the PCV13 era was calculated by
a t test. The microbiome based sum of powered score
tests (MiSPU; R package and command MiSPU) was
performed to investigate the effect of the vaccine era on
the bacterial microbiota composition [40]. The MiSPU
was performed using the OT abundance-based matrix as
input and age, season, the season of birth, symptoms of
LRTI, and the infant identifier as covariates. The phylo-
genetic tree of the OT matrix was rooted at the group of
“others.” Graphical representations and statistical ana-
lyses were either performed in R version 3.3.0 or in
GraphPad Prism version 7.01 (GraphPad Software, La
Jolla, CA).
Results
Study cohort and samples
This study included 41 infants, who received two doses
of PCV within the first year of life (Table 1). Samples
were collected between April 2010 and December 2013.
After exclusion of low-quality samples and samples ob-
tained during antibiotic therapy, a total of 763 samples
were included. This corresponds to a mean (±standard
deviation (SD)) of 18.6 (±3.3) samples per infant. In our
study cohort, 20 infants were vaccinated with PCV7
(n = 355 samples) and 21 infants with PCV13 (n = 408
samples). The recommended vaccination schedule for
PCV in Switzerland is at 2, 4, and 11–15 months of age.
Note that none of the infants included here received the
third dose of PCV before the 12th month of age. The
mean age (±SD) at the first and the second dose was
10.1 (±3.6) and 18.9 (±4.1) weeks, respectively (Table 1).
We compared different risk and confounding factors be-
tween PCV7- and PCV13-vaccinated infants and found
that the season of birth and symptoms of LRTI differed
significantly between the two groups (Table 1; 2 × 4 chi-
square test and unpaired t test; P = 0.03 and P = 0.05,
respectively). We subsequently added these two poten-
tially confounding factors to our LME and NBR models.
Lower pneumococcal carriage in the PCV13 era
We performed qPCR of the pneumococcal lytA gene to
analyze pneumococcal carriage within the first year of
life. When the data was analyzed quantitatively, there
was no significant difference in pneumococcal carriage
between the PCV7 and the PCV13 era (Fig. 1a, b). How-
ever, when the number of samples positive for pneumo-
coccal carriage (>10 lytA copies) was analyzed, we
found, in contrast, a significantly lower carriage in the
PCV13 era (Fig. 1c, d and Additional file 1: Table S1;
LME model; P = 0.01). This was also true using a univar-
iate LME (data not shown). These results indicate a de-
creased pneumococcal carriage in the PCV13 era. We
therefore hypothesized that the different pneumococcal
colonization in the PCV13 era could lead to a change in
the microbiota profile.
Oligotyping of the bacterial Core microbiota
We investigated the impact of the PCV13 and the PCV7 era
on the nasal microbiota based on 16S rRNA sequencing. The
763 samples analyzed for this study produced amean number
(±SD) of 1227.3 sequence reads (±924.4) per sample. We se-
lected the reads of the five most abundant bacterial families
(Moraxellaceae, Streptococcaceae, Staphylococcaceae, Pas-
teurellaceae, and Corynebacteriaceae), which were defined as
the core microbiota, and performed oligotyping. Oligotyping
results in a more precise taxonomic assignment as compared
to the OTU output as it relies on distinct single-nucleotide
polymorphisms (SNPs). In total, we identified 19 oligotypes
(OTs) (Fig. 2 and Additional file 1: Table S2) and exact SNP
position due to E. coli numbering was received (Additional
file 1: Table S2).Within the bacterial family of Pasteurellaceae,
we found six oligotypes which were taxonomically assigned as
Haemophilus influenzae. The Staphylococcaceae OTs were
differentiated into Staphylococcus aureus (OTs Sta1 and Sta3)
and coagulase-negative Staphylococci (OTs Sta2 and Sta4).
However, oligotyping was not able to differentiate between
Moraxella catarrhalis andMoraxella nonliquefaciens, as well
as it was not able to differentiate between Streptococcus pneu-
moniae and Streptococcus pseudopneumoniae. While for the
differentiation of Moraxella spp. the analysis of V1–V3 is
likely to be superior (data not shown), it is known that the
whole 16S rRNA gene is not able to clearly identify S. pneu-
moniae which is, in part, due to conservation of the 16S rRNA
sequence within theMitis group of streptococci [24].We next
compared the relative abundance of OTs between the PCV7
and the PCV13 era. The relative abundance of the OTs was
not normally distributed; we therefore used a NBR model for
this analysis. We found OTs P2 (H. influenzae 2) and P3 (H.
influenzae 3) significantly increased in the PCV13 era, but OT
C2 (Corynebacterium accolens) decreased as compared to the
PCV7 era (Fig. 2 and Additional file 1: Table S2; NBR model;
P = 0.03, P = 0.005, and P = 0.04, respectively). The later,
however, was not significant after correction for multiple
testing with Benjamini-Hochberg (BH). In order to account
for the low-abundant OTs we repeated the analysis using the
binary-based matrix of the OTs and the LMEmodel for ana-
lysis (Fig. 2 and Additional file 1: Table S2). In contrast to the
abundance-based output, the binary-based analysis resulted
in several different significantly increased OTs in the PCV13
era (Fig. 2 and Additional file 1: Table S2; NBR model;
OTs P2 (H. influenzae 2), P3 (H. influenzae 3), P6 (H.
influenzae 6), Sta1 (S. aureus), M2 (Moraxella lincol-
nii), Stre2 (S. dentisani/oralis/tigurinus/oligofermen-
tans/infantis); P = 0.001, P = 0.0001, P = 0.002,
P = 0.04; P = 0.0004, P = 0.003, respectively).
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Table 1 Characteristics of the study population and comparison of risk and confounding factors between PCV7- and PCV13-vaccinated infants
Characteristic PCV7 PCV13 P value
Number of infants, n (%) 20 (48.8%) 21 (51.2%)
Gender (male), n (%) 10 (50%) 9 (42.9%) 0.76#
Season of birth, n (%) 0.03#
Winter 2 (10%) 8 (38.1%)
Spring 4 (20%) 8 (38.1%)
Summer 7 (35%) 3 (14.3%)
Fall 7 (35%) 2 (9.5%)
aParental education, n (%) 0.51#
Low 2 (10%) 4 (19.1%)
Middle 6 (30%) 8 (38.1%)
High 12 (60%) 9 (42.9%)
bHA nutrition, n (%) 4 (20%) 4 (19.1%) 0.94#
C-section, n (%) 3 (15%) 3 (14.3%) 0.95#
cChildcare, n (%) 5 (25%) 5 (23.8%) 0.93#
Smoking during pregnancy, n (%) 2 (10%) 1 (4.8%) 0.52#
dSmoking exposure in the 1st year, n (%) 2 (10%) 5 (23.8%) 0.24#
eMaternal atopy, n (%) 6 (30%) 4 (19.1%) 0.41#
Siblings, n (%) 0.18#
0 3 (15%) 5 (23.8%)
1 9 (45%) 13 (61.9%)
≥2 8 (40%) 3 (14.3%)
Gestational age at birth [weeks], mean (±SD) 39.8 (±1.2) 39.4 (±2.1) 0.45$
Length at birth [cm], mean (±SD) 49.6 (±1.7) 49.7 (±2.0) 0.78$
Weight at birth [g], mean (±SD) 3403.5 (±334.2) 3343.3 (±581.2) 0.69$
Breastfeeding duration [months], mean (±SD) 8.6 (±2.7) 9.3 (±2.9) 0.44$
fAge at PCV administration [weeks], mean (±SD)
1st dose 9.6 (±1.8) 10.6 (±4.8) 0.34$
2nd dose 18.9 (±2.4) 18.9 (±5.5) 0.97$
gHib administration, n, mean age [weeks] (±SD)
1st dose 20, 9.6 (±1.8) 21, 9.6 (±1.1) 0.96$
2nd dose 20, 18.9 (±2.4) 21, 18.2 (±1.1) 0.28$
3rd dose 18, 27.1 (±1.9) 21, 27.2 (±1.6) 0.87$
Respiratory symptoms, n, mean per infant (±SD)
Total 127, 6.4 (±2.7) 134, 6.4 (±3.1) 0.97$
Rhinitis 99, 5.0 (±2.4) 125, 6.0 (±2.9) 0.24$
hURTI 71, 3.6 (±2.2) 76, 3.6 (±2.4) 0.92$
iLRTI 7, 0.35 (±0.8) 21, 1.0 (±1.2) 0.05$
Wheezing 2, 0.1 (±0.3) 6, 0.3 (±0.7) 0.29$
Statistically significant differences were indicated in italics
SD standard deviation
aParental education was categorized into low (less than 4 years of apprenticeship), middle (at least 4 years of apprenticeship), or high (tertiary education)
bHA nutrition (hypoallergenic nutrition) was defined as feeding of hypoallergenic milk supplements at any time point within the first year of life
cChildcare was defined as attending childcare at any time point within the first year of life
dSmoking exposure due to the father and/or the mother smoking within the first year of life of the infant
eMaternal atopy was defined as asthma, hay fever, or eczema
fThe PCV (pneumococcal conjugate vaccine) vaccination schedule is at 2, 4, and 11–15 months Note that all infants obtained the first and the second but not the
third dose within the first year of life
gHib (Haemophilus influenzae type b) vaccination schedule is at 2, 4, 6, and 15–24 months of age. None of the infants got the fourth dose within the observed study
period. In Switzerland, the vaccine is recommended as a combination vaccine with diphtheria, tetanus, pertussis, and poliomyelitis
hURTI: Symptoms of upper respiratory tract infection (URTI) was defined as typical upper respiratory tract symptoms, whereas cough and/or wheeze had to be present
iLRTI: Symptoms of lower respiratory tract infection (LRTI) was defined as cough, wheeze or breathing difficulties, combined with upper respiratory tract symptoms
or elevated body temperature for more than two consecutive days
#Statistical testing of categorical variables was performed by a 2 × 2, 2 × 3, or 2 × 4 chi-square test
$Statistical testing of continuous variables was performed by unpaired t tests
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Increased bacterial diversity in the PCV13 era
The increased pneumococcal carriage in samples from
PCV7-vaccinated infants let us further hypothesize a de-
creased alpha diversity (within-sample diversity) in the
PCV7 era, due to a potential dominance of a bacterial
community member. Based on the binary-based input
matrix, we calculated the number of OTs (richness) and
found that samples from the PCV13 era had, indeed, a
constantly significantly higher richness within the first
year of life (Fig. 3a, b and Additional file 1: Table S1;
LME model; P = 0.003). We also calculated the Shannon
Diversity Index (SDI) based on the relative abundance of
the OTs and found that the SDI was significantly increased
in the PCV13 era, too (Fig. 3c, d and Additional file 1:
Table S1; LME model; P = 0.01). This was also true using a
univariate LME (data not shown).
We next investigated the beta diversity (between-sam-
ple diversity) of samples from the PCV7 and the PCV13
era and performed abundance- and binary-based NMDS
analyses (Fig. 4a, b. We used the multivariate testing
method MiSPU (microbiome-based sum of powered
score tests correcting for the covariates age, season, symp-
toms of LRTI, the season of birth, and the infant identi-
fier) to calculate the difference between the overall
microbiota composition in the PCV7 and the PCV13 era.
The test revealed that the vaccine era had an effect on the
microbiota composition, which was, however, not statisti-
cally significant (MiSPU; P = 0.06). We then looked at the
Jaccard dissimilarity of each study infant longitudinally
within the first year of life. We found no difference of the
abundance-based Jaccard dissimilarity by age using the
LME model (Fig. 4c, d and Additional file 1: Table S1).
There was, however, a trend of a decreased Jaccard
dissimilarity in the PCV13 as compared to the PCV7 era
using the binary-based input matrix (Fig. 4e, f and
Additional file 1: Table S1; LME model; P = 0.06). These
A) B)
C) D)
Fig. 1 Pneumococcal carriage. Samples from the PCV7 era (blue, n = 355) were compared to samples from the PCV13 era (red, n = 408). Shown
are the raw data (a, c) and the fitted data (b, d) using linear mixed effect (LME) models. The fixed effects were age, season, season of birth, symptoms
of lower respiratory tract infection (LRTI), and vaccine era. The random effects were intercepts for the infants and by-infant random slopes for the effect
of the vaccine era. Lines are based on a local polynomial regression fitting (loess function in R). Gray bands indicate the standard deviation (SD). a
Pneumococcal carriage as measured by the lytA quantity (log transformed). b Fitted values of the lytA quantity using the LME model. There was no
significant difference between the PCV7 and the PCV13 era (LME model; P = 0.12). c Number of samples positive for pneumococcal carriage as defined
by >10 lytA copies. d Fitted values of the number of samples positive using the LME model. Significantly lower number of samples positive for lytA in
the PCV13 as compared to the PCV7 era (LME model; P = 0.01)
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results indicate a higher stability of the microbiota com-
position over time in samples of PCV13- as compared to
PCV7-vaccinated infants.
Increased cluster diversity and stability in the PCV13 era
We next performed hierarchical clustering based on the
relative abundance of the OTs. We obtained 10 different
clusters, which were each dominated by at least one OT
(Fig. 5). Correlation analysis revealed a positive correlation
of clusters 1, 5, and 7 with the PCV7 era (Fig. 5; coefficient
0.18, 0.10, and 0.13; P < 0.0001, P = 0.007, and P = 0.0003,
respectively). Regarding the PCV13 era, we found a posi-
tive correlation with clusters 2, 6, and 8 (Fig. 5, coefficients
0.13, 0.10, and 0.08; P = 0.0005, P = 0.006 and P = 0.04, re-
spectively). We calculated the SDI of each cluster and
found that the PCV13-associated cluster 2 had the highest
SDI among the ten different clusters. In contrast, the
PCV7-associated clusters were among those with the low-
est SDI (Additional file 1: Table S3).
Defining a microbiota with a lower diversity and a
higher dissimilarity as potentially instable [41], we hy-
pothesized a decreased cluster stability of bacterial com-
munities in the PCV7 as compared to the PCV13 era.
Thus, we calculated the Jensen–Shannon distances based
on the cluster matrix as input. By definition, communities
that remain in the same cluster over time display a high
level of stability, while those often switch between clusters
have low levels of stability [38]. We found that infants vac-
cinated in the PCV13 era changed less between the clus-
ters and thus had a significantly lower mean Jensen–
Shannon distance as compared to infants vaccinated in
the PCV7 era (Fig. 6a, b, Additional file 1: Table S1, and
Additional file 2; t test; P = 0.03).
Discussion
Here, we performed a case–control study with samples
from a longitudinal infant cohort, investigating the effect
of PCV7 as compared to PCV13 on pneumococcal car-
riage and the nasal microbiota composition in healthy
infants within the first year of life in Switzerland. The
density of pneumococcal carriage remained unchanged,
but in contrast, the number of samples positive for S.
pneumoniae was decreased in the PCV13 era, which
could indicate a higher effectiveness of the PCV13 as
compared to the PCV7 in reducing carriage. Further-
more, we found significant differences in the microbiota
composition between infants vaccinated in the PCV7
and the PCV13 era. Samples from the PCV13 era were
characterized by an increased sample diversity and rich-
ness as compared to samples from the PCV7 era. In ac-
cordance, the PCV13 era was associated with clusters of
a high diversity. In addition, the within-subject micro-
biota dissimilarity (based on the binary distance matrix)
and the Jensen–Shannon distance was decreased in
Fig. 2 Oligotyping of the bacterial core microbiota. Indicated are the bacterial families of the core microbiota and the corresponding oligotypes
(OTs), single-nucleotide polymorphisms (SNPs), and the taxanomic assignment. The latter was derived by choosing a representative sequence of
each OT, which was defined as the most abundant unique sequence belonging to an OT, and assigning the taxanomy by using BLAST (Basic Local
Alignment Search Tool). A negative binomial regression (NBR) model was used for the relative abundance of the OTs and a linear mixed effect (LME)
model for the binary-based analysis. The fixed effects of both models were age, season, season of birth, symptoms of lower respiratory tract infection
(LRTI), and vaccine era. The random effects were intercepts for the infants and by-infant random slopes for the effect of the vaccine era. The PCV7 era
(n = 355 samples) was compared to the PCV13 era (n = 408 samples), whereas the PCV7 era was used as baseline. Inputs were either the relative
abundance of the OTs (abundance-based NBR model) or the binary matrix (binary-based LME model). Indicated are the Estimates and the Standard
Errors. Abundance-based NBR: OT P2 (H. influenzae 2) and P3 (H. influenzae 2) significantly increased and OT C2 (C. accolens) decreased in the PCV13
era as compared to the PCV7 era (P = 0.03, P = 0.005, and P = 0.04, respectively). Binary-based LME: following OTs were significantly increased in the
PCV13 era: P2 (H. influenzae 2), P3 (H. influenzae 3), P6 (H. influenzae 6), Sta1 (S. aureus 1), M2 (M. lincolnii 2), and Stre2 (S. dentisani/oralis/tigurinus/oligofer
mentans/infantis) (P = 0.001, P = 0.0001, P = 0.002, P = 0.04, P = 0.0004, and P = 0.003, respectively)
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infants born in the PCV13 era, indicating higher micro-
biota stability in the PCV13 era.
Infection with S. pneumoniae starts with upper airway
colonization, which might progress to invasive disease if
immunological barriers are crossed. In order to protect
from invasive pneumococcal disease, colonization needs
therefore to be prevented [2, 3]. With the introduction
of the PCVs, pneumococcal serotype replacement and a
decrease of pneumococcal carriage has been described
[42, 43]. In our study, 16S rRNA sequencing and subse-
quent oligotyping did not allow to reliably differentiate
between S. pneumoniae and other members of the
Streptococcus mitis group, such as S. pseudopneumoniae.
This problem has been previously acknowledged [44],
and strategies how to tackle this issue have been ad-
dressed [45]. In our study, we performed qPCR of the
lytA gene, which was shown to be highly specific for S.
pneumoniae [25, 46–48]. We found that the presence of
S. pneumoniae was lower in the PCV13 as compared to
the PCV7 era. In contrast, the microbiota diversity was
increased in samples from the PCV13 era. Together,
these results are in line with previous studies, where the
carriage rates of S. pneumoniae, but also the potential
pathogens M. catarrhalis and H. influenzae have been
associated with a lower diversity of the upper respiratory
tract microbiota in children [21]. Furthermore, concerns
have already been raised over the increased carriage of
potential pathogens, such as H. influenzae, upon vaccin-
ation with PCV [49, 50]. In accordance with these
culture-based studies, we found an increase of a specific
H. influenzae (oligotype P2) in the PCV13 era. However,
this increased abundance was not associated with a dis-
ordered microbiota or an increased risk of symptoms of
upper respiratory tract infections (URTI) in the PCV13
era. It seems, in general, challenging to define specific bac-
terial genera to be predictive for an increased risk of
A) B)
C) D)
Fig. 3 Alpha diversity of the bacterial core microbiota. Samples from the PCV7 era (blue, n = 355) were compared to samples from the PCV13 era
(red, n = 408). Shown are the raw data (a, c) and the fitted data (b, d) using linear mixed effect (LME) models. The fixed effects were age, season,
season of birth, symptoms of lower respiratory tract infection (LRTI), and vaccine era. The random effects were intercepts for the infants and by-infant
random slopes for the effect of the vaccine era. Lines are based on a local polynomial regression fitting (loess function in R). Gray bands indicate the
standard deviation (SD). Inputs are based on the relative abundance or the prevalence of oligotypes (OT). a OT richness as calculated by
the binary-based matrix. b Fitted values of the OT richness. Significantly higher richness in the PCV13 era as compared to the PCV7 era
(LME model; P = 0.003). c Shannon Diversity Index (SDI) as measured by the relative abundance-based input. d Significantly higher SDI in
the PCV13 era as compared to the PCV7 era (LME model; P = 0.01)
Mika et al. Microbiome  (2017) 5:85 Page 9 of 14
respiratory infections: An Australian study found that
transient incursions of Streptococcus, Moraxella, or
Haemophilus marked virus-associated acute respiratory
infections, while a Dutch study, in contrast, found fewer
URTIs in Moraxella-dominated microbiota profiles [51,
52]. A recent prospective cohort study from the USA
investigating the nasopharyngeal microbiota in healthy
children aged 49–84 months, found that the time to de-
velop an URTI was significantly positively correlated with
the microbiota diversity, and children who experienced
more frequent URTIs were found to harbor a microbiota
of reduced diversity [53]. Even though we did not observe
A) B)
C) D)
E) F)
Fig. 4 Beta diversity of the bacterial core microbiota. Samples from the PCV7 era (blue, n = 355) were compared to samples from the PCV13 era
(red, n = 408). Non-metric multidimensional scaling (NMDS) was performed based on the Jaccard dissimilarity matrix of a the abundance-based
and b the binary-based oligotype (OT) input. Within-subject Jaccard dissimilarity was longitudinally analyzed by age. Shown are the raw data (c,
e) and the fitted data (d, f) using linear mixed effect (LME) models. The fixed effects were age, season of birth, and vaccine era. The random
effects were intercepts for the infants and by-infant random slopes for the effect of the vaccine era. Lines are based on a local polynomial regression
fitting (loess function in R). Gray bands indicate the standard deviation (SD). c Abundance-based within-subject Jaccard dissimilarity within the first year
of life. d Fitted values of the abundance-based within-subject Jaccard dissimilarity. There was no significantly different dissimilarity between the PCV7
and the PCV13 era (LME model; P = 0.64). e Binary-based within-subject Jaccard dissimilarity within the first year of life. f Fitted values of
the binary-based within-subject Jaccard dissimilarity. There was a trend of an increased dissimilarity of the PCV7 as compared to the PCV13 era
using the LME model (LME model; P = 0.06)
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a difference in the prevalence of URTI symptoms between
PCV7- and PCV13-vaccinated infants, the abovemen-
tioned studies suggest that the microbiota diversity, rather
than specific bacterial genera, could serve as a marker to
predict the susceptibility of infections.
In addition to the increased diversity, we identified in-
creased microbiota stability in infants vaccinated with
PCV13 as compared to PCV7. The higher microbiota
stability might be a result of the increased diversity, in
so far as a diverse microbiota could indicate the presence
of commensal species rather than pathobionts, whereas
the latter might be associated with a fluctuating and insta-
ble microbiota [21]. Only recently, commensal genera
such as Corynebacterium and Dolosigranulum were asso-
ciated with niche stability over time [54]. In similar man-
ner, the gram-positive Alloiococcus was described as a
stable component of the healthy nasopharyngeal micro-
biota, which was associated with an enhanced overall sta-
bility of the microbiota [51]. In addition to the increased
diversity as discussed above, the higher stability of the
microbiota in the PCV13 era could therefore indicate a
lower susceptibility to infectious diseases of the upper air-
ways because of the lower turnover of bacterial com-
munities [38]. Indeed, lower incidence rates of acute
otitis media have already been reported upon PCV13
but not as much upon PCV7 introduction [55, 56]. In our
study here, we observed no difference in the number of
symptoms from URTIs between PCV7- and PCV13-
vaccinated infants. However, an overall reduction of
acute otitis media cases in the PCV13 era in
Switzerland has been observed [57]. Overall, this indi-
cates that the lower carriage rate and the higher
Fig. 5 Cluster analysis. Indicated are the clusters, the correlation coefficients of the PCV7 (n = 355 samples and n = 20 infants) and the PCV13 era
(n = 408 samples and n = 21 infants), and the P values. On the right, the composition of the clusters based on the oligotypes (mean relative
abundances) is shown. A positive correlation was found for clusters 1, 5, and 7 with the PCV7 era (coefficients 0.18, 0.10, and 0.13; P < 0.0001,
P = 0.007, and P = 0.0003, respectively), and for clusters 2, 6, and 8 with the PCV13 era (coefficients 0.13, 0.10, and 0.08; P = 0.0005, P = 0.006 and
P = 0.04, respectively). Significantly positive correlations are indicated in bold
A) B)
Fig. 6 Cluster stability of the bacterial core microbiota. Cluster stability was calculated by the Jensen–Shannon distance based on the cluster
matrix as input. A lower Jensen–Shannon distance indicates a higher stability because fewer switches between clusters occur. a Indicated is the
within-subject Jensen–Shannon distance for each infant. Infant numbers 1–20 were vaccinated with the PCV7 and infant numbers 21–41 with the
PCV13. b The mean within-subject Jensen–Shannon distance between PCV7-vaccinated infants (n = 20) and PCV13-vaccinated infants (n = 21)
was compared. There was a significantly lower mean Jensen–Shannon distance in the PCV13 era as compared to the PCV7 era (t test; P = 0.03).
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diversity could lead to a lower susceptibility of respira-
tory tract infections in PCV13- as compared to PCV7-
vaccinated infants.
Our study has some major strengths: To our best
knowledge, this is the first study comparing the nasal
bacterial microbiota between PCV7- and PCV13-
vaccinated infants using a longitudinal study design. Fur-
thermore, we performed oligotyping, which improved
the resolution of the taxonomic assignments in compari-
son to the standard taxon-based assignment [58]. This
allowed us to identify some reliable changes of commu-
nity members upon vaccination with the PCVs up to the
species level. In addition, performing a longitudinal
study allowed the investigation of the stability—a marker
of bacterial turnover—of the microbiota. Therefore, this
study could be used to assist in analyzing cross-sectional
studies of the nasal microbiota in infants.
A limitation of this study is the absence of pre-vaccine
era samples, which did not allow comparing the PCV7
and the PCV13 era to the era before the implementation
of the PCVs. Therefore, we were only able to investigate
the changes upon replacement of the PCV7 by the
PCV13. However, different studies already showed a big-
ger impact of the PCV13 on the pneumococcal carriage
as compared to PCV7 [59, 60]. This replacement clearly
induced a change in the nasal microbiota and is thus of
importance not only in Switzerland but also in other
countries with similar vaccination schedules.
Furthermore, our observed changes cannot clarify if our
findings are additionally influenced by herd protection
due to early and/or late consequences of the PCV13 or
PCV7 introduction, respectively. We only can say that we
noted the changes in the PCV13 era. As for the decrease
of pneumococcal carriage in the PCV13 era, this has also
recently been described in a rather large cross-sectional
study investigating pneumococcal carriage in patients with
acute otitis media in Switzerland [57]. In combination
with this study, this may indicate that non-PCV13 sero-
types may not colonize equally well and, therefore, this
may vacate the niche for other “colonizers.”
It has also to be noted that we did not analyze the en-
tire microbiota with oligotyping but only the most abun-
dant bacterial families. Therefore, a more in-depth
inclusion of “others” may have led to different and/or
additional conclusions. However, we hypothesized that
the pneumococcal conjugate vaccines may only have
subtle consequences on specific members of the bacter-
ial families with the highest abundances (core micro-
biota) and, therefore, a more depth analysis of these
families using oligotyping would be superior in this case
as compared to the more general 97% OTU approach of
the entire microbiota.
Another limitation of the study is the small sample
size including only 41 infants. However, we provide an
extreme dense longitudinal sampling which allows an in-
depth analysis of the stability of the microbiota within
the first year of life.
Conclusions
This study shows changes in the nasal microbiota com-
position between infants vaccinated in the PCV7 and the
PCV13 era. Importantly, samples from the PCV13 era
were associated with a higher diversity and stability,
which might be consistent with a lower susceptibility to
respiratory tract infections. However, whether this hy-
pothesis holds true, needs further investigations—not
only by conventional culture studies but also by longitu-
dinal, sequencing-based microbiota analyses.
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